logo
Vitalité tells Canadian Health Labs' travel nurses not to come to work

Vitalité tells Canadian Health Labs' travel nurses not to come to work

CBC04-03-2025

Vitalité Health Network has cancelled the remaining shifts of travel nurses employed by Canadian Health Labs, even though its controversial contract with the Toronto-based staffing agency doesn't expire until next year.
Premier Susan Holt confirmed the move to CBC News Tuesday morning during a news conference about the province's action plan in response to 25 per cent tariffs imposed by U.S. President Donald Trump.
"Vitalité has been taking aggressive action to get us out of a bad contract," said Holt.
"We know that the CHL contract has been a source of frustration, cost and an issue for New Brunswickers and an issue for our nurses who watched folks come into our province, get paid significantly more than them and see some of them lose shifts and lose opportunities," she said.
"So we are glad to be getting out of that contract and focusing on New Brunswick nurses, who we need to retain and support for the long-term health of our health-care system."
Contract remains in effect
Vitalité declined an interview request, but in an emailed statement said it remains in discussions with Canadian Health Labs.
"Given the confidential nature of these discussions and the ongoing dispute, we will not comment on the specific details of the matter. However, we can confirm that our contract with CHL remains in effect to this day," the unsigned statement said in French.
The regional health authority did not immediately respond to questions, such as whether it's still paying the company, or how it's staffing its hospitals and nursing homes without the private agency nurses.
Canadian Health Labs did not immediately respond to a request for comment.
Auditor general slammed contracts
The agreement between Vitalité and the company was the subject of a scathing report by Auditor General Paul Martin in June.
While the health system was facing dire staffing shortages in 2022 when the authority signed its first contract with Canadian Health Labs, the deployment of travel nurses in Vitalité's hospitals "did not correlate with staff absences due to COVID-19," Martin said.
"The contracts with private nursing agencies were not reflective of best practices and did not demonstrate value for money," he said.
What is "quite scary," Martin told MLAs at the time, is that the current Canadian Health Labs contract with Vitalité allows the company to deploy nurses "regardless of the actual need" and still be paid up to $85 million during the life of the agreement.
Vitalité recorded a deficit of $52.1 million during the first six months of the current fiscal year, with travel nurses accounting for $44.2 million of that, board member Réjean Després said during January's board meeting.
Intends to accelerate 'weaning plan'
In its statement Tuesday, Vitalité reiterated its commitment to gradually reduce its reliance on staffing agencies.
It has already "significantly" reduced the use of travel nurses through a "weaning plan," which began in the fall of 2023, it said, and plans to accelerate the process this year, with the arrival of new hires, including professionals currently being certified in Canada and nursing graduates from post-secondary institutions in the province.
"Our goal of ending our use of agencies by February 2026 remains unchanged," Vitalité said, declining further comment.
Union president pleased
Paula Doucet, president of the New Brunswick Nurses Union, who has long called for an end of the use of costly private agency nurses, said she hadn't heard confirmation of the latest development.
But she did hear a few weeks ago about some nurses employed by Canadian Health Labs who were advised not to go to work at Chauleur Regional Hospital.
"They were just told not to show up for their shift and to return their work badges," she said.
"I believe it was Chad Doucet, [administrative director of clinical services and professional practice], that sent the e-mail to them and they were to contact him if they had any questions or concerns."
Doucet said it's "about time" New Brunswick gets rid of travel nurse contracts and invests in retaining existing nurses and recruiting more.
"It's a no-win every time we spend money on private for-profit entities that take taxpayer dollars out of our province."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

PointClickCare Pledges $75,000 to the Senior Living CaRES Fund in Support of Education Grants for Senior Living Workers
PointClickCare Pledges $75,000 to the Senior Living CaRES Fund in Support of Education Grants for Senior Living Workers

Cision Canada

time3 hours ago

  • Cision Canada

PointClickCare Pledges $75,000 to the Senior Living CaRES Fund in Support of Education Grants for Senior Living Workers

Leading health tech company commemorates National Long-Term Care Day with three-year commitment aimed at strengthening and empowering Canada's senior living workforce TORONTO, June 13, 2025 /CNW/ -- PointClickCare, a leading health tech company helping providers deliver exceptional care, today announced a three-year philanthropic partnership with the Senior Living CaRES Fund. The company will contribute $25,000 annually — totaling $75,000 — to fund educational grants that support professional development for workers in long-term care and retirement communities across Canada. Founded in 2020, the Senior Living CaRES Fund has provided over $3 million in emergency financial assistance and educational grants to frontline workers. The fund recognizes the vital role senior living professionals play in caring for older adults and is committed to fostering a stronger, more resilient workforce. "At PointClickCare, we believe that investing in people is the most meaningful way to drive lasting impact," said Angeline Pleunis, Vice President, Workplace Experience & Social Impact at PointClickCare. "The individuals working in senior living communities play an essential role in the health and well-being of our aging population, and they deserve every opportunity to grow, thrive, and succeed in their careers. Our partnership with the Senior Living CaRES Fund reflects our deep commitment to supporting this incredible workforce through education and development." The COVID-19 pandemic highlighted significant challenges in long-term care and heavily burdened frontline staff. These workers showed, and continue to show, remarkable resilience and compassion, often making personal sacrifices. It's clear that investing in their education and development is essential. PointClickCare's support enhances access to continuing education and training, equipping staff to excel in their careers and improve care quality. "We are incredibly grateful for PointClickCare's generous commitment to the Senior Living CaRES Fund," said Rebecca Scott Rawn, Executive Director at Senior Living CaRES Fund. "Their support will directly empower frontline workers with access to education and professional development opportunities – tools that not only enhance individual careers but strengthen the quality of care for seniors across Canada. Together, we are investing in the champions who make compassionate care possible every day." On National Long-Term Care Day, PointClickCare and the Senior Living CaRES Fund are proud to honour the dedication of those working in senior living communities. Together, they are investing in a future where every senior living worker feels valued, supported, and empowered to make a lasting impact. To learn more about PointClickCare's award-winning culture and philanthropic programs, visit the website here. For more information on the Senior Living CaRES Fund, visit the website here. About PointClickCare PointClickCare is a leading health tech company with one simple mission: to help providers deliver exceptional care. With the largest long–term and post–acute care dataset, we power AI-driven healthcare to deliver intelligent transitions, insightful interventions, and improved financial performance. Enhanced by our marketplace of 400+ integrated partners and trusted by over 30,000 provider organizations and every major U.S. health plan, we're redefining healthcare, so it doesn't just survive — it thrives. About The Senior Living CaRES Fund Established in May 2020 by founding partners Chartwell Retirement Residences, Revera Inc., Extendicare, and Sienna Senior Living, the Senior Living CaRES Fund was created in recognition of the extraordinary efforts of senior living sector employees whose passion, commitment and resilience while caring for the most vulnerable is nothing short of heroic. Since its establishment, the Fund has assisted over 970 employees across the country, distributing more than $3.1 million in emergency financial aid and bursaries for education.

New York Festivals Advertising Awards Announces Milestone Win; Names Klick Health 'Agency of the Year'
New York Festivals Advertising Awards Announces Milestone Win; Names Klick Health 'Agency of the Year'

National Post

time3 hours ago

  • National Post

New York Festivals Advertising Awards Announces Milestone Win; Names Klick Health 'Agency of the Year'

Article content Accolade marks first time the consumer advertising show gives top prize to a health agency; Klick also takes home 17 Towers, including Grand Award in Film Craft Article content NEW YORK & TORONTO — Klick Health was named 'Agency of the Year' by New York Festivals Advertising Awards (NYFA) yesterday, representing a landmark win for the independent health agency and signaling a turning point in consumer advertising, as health increasingly becomes more mainstream. The news marks the third Agency of the Year distinction for Klick in under a month after being named Clio Health's Independent Agency of the Year for the third consecutive year earlier this week, and also making history as the first health agency to be named an Agency of the Year by The One Show. Article content Scott Rose, New York Festivals Advertising Awards President said, 'We're thrilled to celebrate Klick Health's extraordinary success in the 2025 NYFA. This marks the first time a health agency has earned the prestigious title of Agency of the Year, a milestone that speaks to the power of Klick's innovative and purpose-driven creativity. Among their many award-winning campaigns, the Grand Award-winning '47' stands out as a powerful testament to inclusion, resilience, and the transformative impact of storytelling.' Article content 'We are incredibly proud to be recognized among the world's top agencies by the NYFA,' said Klick Health Chief Creative Officer Rich Levy. 'As the first health-focused agency to be named Agency of the Year, it's inspiring to see creativity in health continue to take its place on the global stage and a testament to the quality of work being done throughout the healthcare industry.' Article content With entries from six continents judged by an international jury of more than 350 members, the NYFA jury pushed forward work that puts brands in the spotlight and resonates with today's consumers. Among the top accolades, Klick received the Grand Award in Film Craft, eight Gold Towers, four Silver Towers, and four Bronze Towers for its ' 47,' ' American Cancer Story,' and ' Voice 2 Diabetes ' campaigns. Article content Klick's full list of New York Festivals Advertising Awards Article content AGENCY OF THE YEAR GRAND AWARD: 47 – Café Joyeux – Film Craft – Animation GOLD: 47 – Café Joyeux – Film Craft – Animation GOLD: 47 – Café Joyeux – Film Craft – Best Use of Music GOLD: 47 – Café Joyeux – Film Craft – Production Accomplishment GOLD: 47 – Café Joyeux – Design – Best Use: Art Direction/Production Design GOLD: 47 – Café Joyeux – Design – Best Use: Custom Illustration GOLD: Voice 2 Diabetes – KVI Brave Fund Inc. – Avant-Garde/Innovative: Technology GOLD: Voice 2 Diabetes – KVI Brave Fund Inc. – Best Use: Technology GOLD: Voice 2 Diabetes – KVI Brave Fund Inc. – Best Use: Use of Data SILVER: 47 – Café Joyeux – Design – Branded Content/Entertainment: Craft: Production Accomplishment SILVER: Voice 2 Diabetes – KVI Brave Fund Inc. – Best Use: Innovation SILVER: Voice 2 Diabetes – KVI Brave Fund Inc. – Purpose: Technology for Good SILVER: Voice 2 Diabetes – KVI Brave Fund Inc. – Digital/Mobile: Best Use: Voice Activation BRONZE: American Cancer Story – Change the Ref – Film: Best Use: Social/Environmental Good: NGO/PSA BRONZE: 47 – Café Joyeux – Film Craft: Art Direction/Production Design BRONZE: 47 – Café Joyeux – Purpose: Children – Health, Happiness and Safety BRONZE: Voice 2 Diabetes – KVI Brave Fund Inc. – The Future Now: Effectiveness: Use of AI for Effectiveness Article content About Klick Health Article content Klick Health Article content is the world's largest independent commercialization partner for life sciences, focused on hacking the boundaries of health by developing, launching, and supporting life sciences brands to achieve their full potential. The agency provides best-in-class marketing and advertising, media strategy and purchasing, medical affairs and medical communications, value and market access services, as well as enterprise omnichannel enablement among its specialized offerings. Klick's client service is rooted in deep medical and scientific understanding, enabled by nearly 250 post-graduate, in-house medical experts; unrivaled decision sciences capabilities; and innovative, results-driven creative. Article content One of the most-awarded advertising agencies on the planet, Klick was named 2024 Clio Health Independent Agency of the Year, London International Awards Global (and Regional) Independent Health & Pharma Agency of the Year, as well as Cannes Lions #2 Healthcare Agency and #2 Healthcare Network for the second year running. Cannes Lions also recognized Klick as the 2024 #3 Independent Agency of the Year. In 2024, Klick won over 140 top creative honors, including the coveted Cannes Lions Innovation Grand Prix, and eight agency distinctions from the most respected advertising awards shows. Klick has also been ranked a Best Managed Company, Great Place to Work, Best Workplace for Women, Best Workplace for Inclusion, Best Workplace for Professional Services, Most Admired Corporate Culture, and a FORTUNE Best Workplace in Advertising. Article content Established in 1997, Klick Health (including Klick Katalyst and btwelve) has offices in New York, Philadelphia, Saratoga Springs, Toronto, London, São Paulo, and Singapore. It is part of the Klick Group of companies, which also includes Klick Media Group, Klick Applied Sciences (including Klick Labs), Klick Consulting, Klick Ventures, and Sensei Labs. Follow Klick Health on LinkedIn and for more information on joining Klick, go to Article content Article content Article content Article content Contacts Article content Article content

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

National Post

time4 hours ago

  • National Post

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Article content Article content – Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder ('MDD') with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) – Article content Article content – Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company's commercialization and manufacturing capabilities – Article content – Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin's clinical-stage pipeline – Article content TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update. Article content 'It is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program CYB003 in Phase 3 development, the path toward approval and eventual commercialization of psychedelic therapeutics is gaining clarity,' said Doug Drysdale, Chief Executive Officer of Cybin. 'With our expanded intellectual property portfolio, and a number of key partnerships in place, we believe our rigorous research and novel clinical approach can lead to a transformation in how mental health disorders are treated. Now is the time to address the mental health crisis, and we are encouraged by recent sentiment in favor of expediting the regulatory review process for product candidates in development.' Article content Continued to expand its strategic clinical site partnership ('SPA') program in support of the Phase 3 PARADIGM program. The SPA program is designed to facilitate collaboration among sites, enhance efficiency in trial operations, and improve overall site performance. Partnered with Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003. Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline. Continued to expand intellectual property portfolio with two additional U.S. patents supporting lead programs CYB003 and CYB004, bringing the total to over 90 granted patents and over 230 pending applications. The recently issued patents are as follows: U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041. U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ('IM') injection, including CYB004. Article content Positive Regulatory Signals and Evolving Acceptance of Potential Therapeutic Value of Psychedelics Article content Recent statements and hiring decisions by senior U.S. Health and Human Services ('HHS') and FDA officials, in addition to ongoing signs of bipartisan congressional support, suggest an improved forward regulatory environment for psychedelic medicine and therapies, including the potential for accelerated approval pathways. Article content The Company believes that these developments, together with increased political recognition and public understanding of the science underpinning these programs, have the potential to expedite regulatory pathways and reduce overall risk across its clinical portfolio. Highlights include: Article content In a recent interview, FDA Commissioner Dr. Marty Makary stated that psychedelic-drug review is a 'top priority' and promised an 'expeditious and rapid review' of clinical data. 1 Article content Drug-policy lawyer, Matthew Zorn, has joined HHS as Deputy General Counsel to work on psychedelics policy. He previously challenged the government on matters such as allowing research on cannabis for veterans with PTSD, preventing tryptamines from being scheduled, and fighting for patient access to psilocybin under Right to Try laws. 2 Article content Navy-SEAL-turned-Congressman Morgan Luttrell recently urged the GOP to 'embrace' compounds such as psilocybin, MDMA and ibogaine to help veterans with PTSD. 3 Article content President Trump's new pick for surgeon general, Dr. Casey Means, wrote in a recent book that people should consider guided-psychedelic therapy. 4 Article content On June 19, 2025, Doug Drysdale will speak in a panel discussion focused on the regulatory landscape and next steps for potential commercialization, at the Psychedelic Science 2025 Conference taking place June 16-20, 2025, in Denver, Colorado. The panel details are as follows: Article content Panel Title: Article content Date and Time: Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Sources Article content NewsNation, 'FDA Commissioner Says Research on Psychedelic Treatment 'Top Priority',' interview with FDA Commissioner Dr. Marty Makary, video posted May 16, 2025, (accessed June 9, 2025). Politico, 'A Psychedelics Hire at HHS,' newsletter article, published May 28 2025, (accessed June 9 2025). The Wall Street Journal, 'Lawmaker 'Reborn' Through Psychedelic Therapy Wants the GOP to Embrace It,' news article, published May 17 2025, (accessed June 9 2025). The Associated Press, 'Trump Surgeon General Pick Praised Unproven Psychedelic Therapy, Said Mushrooms Helped Her Find Love,' news article, published May 14 2025, (accessed June 9 2025). Fox News. 'Trump Administration Exploring Potential Benefits of Psychedelic Treatments.' America's Newsroom, correspondent Alexandria Hoff, broadcast June 5 2025. Video clip, 1:58. Article content Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll participants and add additional clinical sites for the PARADIGM program; regulatory statements that suggest an expedited regulatory pathway for Cybin programs; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company's partnership with Osmind; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Article content Contacts Article content Investor & Media: Article content Article content Gabriel Fahel Article content Article content Chief Legal Officer Article content Article content Cybin Inc. Article content Article content Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store